A new U.S. government investigation has found new pneumonia strains impervious to available vaccinations// are fast emerging.
In Alaska, for instance, the native children are already protected against seven strains of pneumococcal disease due to vaccination. But the rate of serious infection by other strains is increasing there by as much as 140 percent.
"The vaccine has been very effective and has done exactly what we hoped it would do. It's decreased the incidence of invasive pneumococcal disease (covered by the vaccine strains) by 95 percent in Alaskan Native children," said the study's lead author, Dr. Rosalyn Singelton, a visiting researcher for the U.S. Centers for Disease Control and Prevention in Anchorage, Alaska. "But, we've recently seen a significant increase in emerging non-vaccine serotypes."
Pneumococcal disease (Pneumonia) is a serious disease that causes sickness and death. Each year, Pneumococcal disease kills more people in the U.S., than all other vaccine-preventable diseases combined.
Anyone can get pneumococcal disease; however, some people are at greater risk. These people include those who are 65 years of age and older or people with special health problems like heart or lung diseases or HIV.
In 2000, the PCV7 pneumococcal conjugate vaccine first became available for infants and children. The vaccine includes the seven strains or serotypes of the bacteria that commonly cause pneumococcal disease in the United States.
Alaskan Natives have traditionally had higher rates of pneumococcal disease, according to the study. Before the introduction of the PCV7 vaccine, Alaskan Native children had three times the rate of invasive pneumococcal disease compared to the overall U.S. population.
Possible reasons for this, according to Singleton, were overcrowding in small households, spending large amounts of time indoors and a lack of running water in many communities.
w study, published in the April 25 issue of the Journal of the American Medical Association, included surveillance data from the beginning of 1995 through 2006.
The researchers found that within three years of the introduction of the vaccine, the overall rates of invasive pneumococcal disease in Alaskan Native children under age 2 was down by 67 percent.
However, when the researchers compared the two-year periods of 2001-2003 to 2004-2006, they saw an 82 percent increase in the rate of overall invasive pneumococcal disease in Alaskan Native children under 2. For strains not covered by the vaccine, the rate jumped by 140 percent compared to the pre-vaccine period.
One strain in particular, serotype 19A, was responsible for almost one-third of the non-vaccine covered disease, according to the study.
Dr. Katherine Poehling, a pediatrician at Brenner Children's Hospital at Wake Forest University School of Medicine in Winston-Salem, N.C., said, "The serotype replacement is occurring to a greater extent in this (Alaskan Native) population, but it will happen in others."
Singleton said that potential ways to reduce the incidence of disease were good hand-washing, breast-feeding your baby if you can, and delaying putting children into day care if possible.
GPL/B Related medicine news :1
. Toxin connected to Flesh-eating Pneumonia in Kids2
. A new Vaccine for Pneumonia 3
. The After Effects Of Pneumonia4
. Acid Suppressive Drugs Found To Increase The Risk for Pneumonia5
. Tsunami Survivors Face Pneumonia Threat6
. New Vaccine Found To Be Effective In Reducing Childhood Pneumonia7
. Zinc Effective In Helping Kids Recover From Pneumonia8
. Bronchiolo-alveolar Carcinoma Shows Sonographic Pattern Of Pneumonia 9
. Pneumonia Claims 30 Lives In Pakistan10
. Pneumonia Vaccine Effective Among Children11
. Pneumonia Effectively Treated with Short-Term Antibiotic Course